|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goss PE, Strasser-Weippl K, Lee-Bychkovsky
BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PER, Pramesh CS,
Badovinac-Crnjevic T, Sheikine Y, et al: Challenges to effective
cancer control in China, India, and Russia. Lancet Oncol.
15:489–538. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Varghese C and Shin HR: Strengthening
cancer control in China. Lancet Oncol. 15:484–485. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li L, Ji J, Wang JB, Niyazi M, Qiao YL and
Boffetta P: Attributable causes of breast cancer and ovarian cancer
in China: Reproductive factors, oral contraceptives and hormone
replacement therapy. Chin J Cancer Res. 24:9–17. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Virchow R: An address on the value of
pathological experiments. Br Med J. 2:198–203. 1881. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shrotriya S, Walsh D, Bennani-Baiti N,
Thomas S and Lorton C: C-reactive protein is an important biomarker
for prognosis tumor recurrence and treatment response in adult
solid tumors: A systematic review. PLoS One. 10:e01430802015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sengupta S, Lohse CM, Cheville JC,
Leibovich BC, Thompson RH, Webster WS, Frank I, Zincke H, Blute ML
and Kwon ED: The preoperative erythrocyte sedimentation rate is an
independent prognostic factor in renal cell carcinoma. Cancer.
106:304–312. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Uribe-Querol E and Rosales C: Neutrophils
in cancer: Two sides of the same coin. J Immunol Res.
2015:9836982015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Palumbo JS, Kombrinck KW, Drew AF, Grimes
TS, Kiser JH, Degen JL and Bugge TH: Fibrinogen is an important
determinant of the metastatic potential of circulating tumor cells.
Blood. 96:3302–3309. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McNamara MG, Templeton AJ, Maganti M,
Walter T, Horgan AM, McKeever L, Min T, Amir E and Knox JJ:
Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract
cancer. Eur J Cancer. 50:1581–1589. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McMillan DC, Crozier JE, Canna K, Angerson
WJ and McArdle CS: Evaluation of an inflammation-based prognostic
score (GPS) in patients undergoing resection for colon and rectal
cancer. Int J Colorectal Dis. 22:881–886. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mano Y, Shirabe K, Yamashita Y, Harimoto
N, Tsujita E, Takeishi K, Aishima S, Ikegami T, Yoshizumi T,
Yamanaka T and Maehara Y: Preoperative neutrophil-to-lymphocyte
ratio is a predictor of survival after hepatectomy for
hepatocellular carcinoma: A retrospective analysis. Ann Surg.
258:301–305. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yodying H, Matsuda A, Miyashita M,
Matsumoto S, Sakurazawa N, Yamada M and Uchida E: Prognostic
significance of neutrophil-to-lymphocyte ratio and
platelet-to-lymphocyte ratio in oncologic outcomes of esophageal
cancer: A systematic review and meta-analysis. Ann Surg Oncol.
23:646–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wariss BR, de Souza Abrahão K, de Aguiar
SS, Bergmann A and Thuler LCS: Effectiveness of four inflammatory
markers in predicting prognosis in 2374 women with breast cancer.
Maturitas. 101:51–56. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu X, Qu JK, Zhang J, Yan Y, Zhao XX,
Wang JZ, Qu HY, Liu L, Wang JS and Duan XY: Prognostic role of
pretreatment neutrophil to lymphocyte ratio in breast cancer
patients: A meta-analysis. Medicine (Baltimore). 96:e81012017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Satoh T, Matsumoto K, Tanaka YO, Akiyama
A, Nakao S, Sakurai M, Ochi H, Onuki M, Minaguchi T, Sakurai H and
Yoshikawa H: Incidence of venous thromboembolism before treatment
in cervical cancer and the impact of management on venous
thromboembolism after commencement of treatment. Thromb Res.
131:e127–e132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Palumbo JS, Talmage KE, Massari JV, La
Jeunesse CM, Flick MJ, Kombrinck KW, Jirousková M and Degen JL:
Platelets and fibrin(ogen) increase metastatic potential by
impeding natural killer cell-mediated elimination of tumor cells.
Blood. 105:178–185. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao K, Deng H, Qin Y, Liao W and Liang W:
Prognostic significance of pretreatment plasma fibrinogen and
platelet levels in patients with early-stage cervical cancer.
Gynecol Obstet Invest. 79:25–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jones JM, McGonigle NC, McAnespie M, Cran
GW and Graham AN: Plasma fibrinogen and serum C-reactive protein
are associated with non-small cell lung cancer. Lung Cancer.
53:97–101. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mei Y, Zhao S, Lu X, Liu H, Li X and Ma R:
Clinical and prognostic significance of preoperative plasma
fibrinogen levels in patients with operable breast cancer. PLoS
One. 11:e01462332016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kijima T, Arigami T, Uchikado Y, Uenosono
Y, Kita Y, Owaki T, Mori S, Kurahara H, Kijima Y, Okumura H, et al:
Combined fibrinogen and neutrophil-lymphocyte ratio as a prognostic
marker of advanced esophageal squamous cell carcinoma. Cancer Sci.
108:193–199. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang W, Wang S, Zhang H, Zhang B and Wang
C: Prognostic significance of combined fibrinogen concentration and
neutrophil-to-lymphocyte ratio in patients with resectable
non-small cell lung cancer. Cancer Biol Med. 15:88–96. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu X, Liu Z, Lin E, Chen Y, Sun X and
Zhou Z: A cumulative score based on preoperative fibrinogen and the
neutrophil-lymphocyte ratio to predict outcomes in resectable
gastric cancer. Cancer Manag Res. 10:3007–3014. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Arigami T, Okumura H, Matsumoto M,
Uchikado Y, Uenosono Y, Kita Y, Owaki T, Mori S, Kurahara H, Kijima
Y, et al: Analysis of the fibrinogen and neutrophil-lymphocyte
ratio in esophageal squamous cell carcinoma: A promising blood
marker of tumor progression and prognosis. Medicine (Baltimore).
94:e17022015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th. Springer;
New York, NY: 2010
|
|
31
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JMS, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American society of
clinical oncology/college of American pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
National Comprehensive Cancer Network, .
The NCCN Breast Cancer Clinical Practice Guidelines in Oncology
(version 1.2012) (EB/OL). https://www.nccn.org/professionals/physician_gls/default.aspx
|
|
33
|
Wang H, Zhao J, Zhang M, Han L, Wang M and
Xingde L: The combination of plasma fibrinogen and neutrophil
lymphocyte ratio (F-NLR) is a predictive factor in patients with
resectable non small cell lung cancer. J Cell Physiol.
233:4216–4224. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Arigami T, Uenosono Y, Matsushita D,
Yanagita S, Uchikado Y, Kita Y, Mori S, Kijima Y, Okumura H,
Maemura K, et al: Combined fibrinogen concentration and
neutrophil-lymphocyte ratio as a prognostic marker of gastric
cancer. Oncol Lett. 11:1537–1544. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Diakos CI, Charles KA, McMillan DC and
Clarke SJ: Cancer-related inflammation and treatment effectiveness.
Lancet Oncol. 15:e493–e503. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Coussens LM, Zitvogel L and Palucka AK:
Neutralizing tumor-promoting chronic inflammation: A magic bullet?
Science. 339:286–291. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lin EY, Nguyen AV, Russell RG and Pollard
JW: Colony-stimulating factor 1 promotes progression of mammary
tumors to malignancy. J Exp Med. 193:727–740. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sparmann A and Bar-Sagi D: Ras-induced
interleukin-8 expression plays a critical role in tumor growth and
angiogenesis. Cancer Cell. 6:447–458. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rokavec M, Wu W and Luo JL: IL6-mediated
suppression of miR-200c directs constitutive activation of
inflammatory signaling circuit driving transformation and
tumorigenesis. Mol Cell. 45:777–789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gabrilovich DI, Ostrand-Rosenberg S and
Bronte V: Coordinated regulation of myeloid cells by tumours. Nat
Rev Immunol. 12:253–268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ohki S, Shibata M, Gonda K, Machida T,
Shimura T, Nakamura I, Ohtake T, Koyama Y, Suzuki S, Ohto H and
Takenoshita S: Circulating myeloid-derived suppressor cells are
increased and correlate to immune suppression, inflammation and
hypoproteinemia in patients with cancer. Oncol Rep. 28:453–458.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Diaz-Montero CM, Salem ML, Nishimura MI,
Garrett-Mayer E, Cole DJ and Montero AJ: Increased circulating
myeloid-derived suppressor cells correlate with clinical cancer
stage, metastatic tumor burden, and doxorubicin-cyclophosphamide
chemotherapy. Cancer Immunol Immunother. 58:49–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Grivennikov SI, Wang K, Mucida D, Stewart
CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung
KE, et al: Adenoma-linked barrier defects and microbial products
drive IL-23/IL-17-mediated tumour growth. Nature. 491:254–258.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Protopsaltis NJ, Liang W, Nudleman E and
Ferrara N: Interleukin-22 promotes tumor angiogenesis.
Angiogenesis. 22:311–323. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH
and Park MH: Interleukin 32, inflammation and cancer. Pharmacol
Ther. 174:127–137. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Guthrie GJ, Charles KA, Roxburgh CS,
Horgan PG, McMillan DC and Clarke SJ: The systemic
inflammation-based neutrophil-lymphocyte ratio: Experience in
patients with cancer. Crit Rev Oncol Hematol. 88:218–230. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Goldenberg N, Kahn SR and Solymoss S:
Markers of coagulation and angiogenesis in cancer-associated venous
thromboembolism. J Clin Oncol. 21:4194–4199. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Simpson-Haidaris PJ and Rybarczyk B:
Tumors and fibrinogen. The role of fibrinogen as an extracellular
matrix protein. Ann NY Acad Sci. 936:406–425. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Baumann H and Gauldie J: The acute phase
response. Immunol Today. 15:74–80. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sahni A, Simpson-Haidaris PJ, Sahni SK,
Vaday GG and Francis CW: Fibrinogen synthesized by cancer cells
augments the proliferative effect of fibroblast growth factor-2
(FGF-2). J Thromb Haemost. 6:176–183. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rybarczyk BJ and Simpson-Haidaris PJ:
Fibrinogen assembly, secretion, and deposition into extracellular
matrix by MCF-7 human breast carcinoma cells. Cancer Res.
60:2033–2039. 2000.PubMed/NCBI
|
|
52
|
Dahl M: Networking with fibrinogen: A
prerequisite for fibroblast growth factor-2 (FGF-2)-stimulated
tumor growth? J Thromb Haemost. 6:174–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
